Please use this identifier to cite or link to this item:
|Scopus||Web of Science®||Altmetric|
|Title:||Drug companies' evidence to justify advertising|
|Citation:||The Lancet, 1989; 334(8674):1261-1264|
|V.A. Wade, P.R. Mansfield, P.J. Mcdonald|
|Abstract:||Ten international pharmaceutical companies were asked by letter to supply their best evidence in support of marketing claims for seventeen products. Fifteen replies were received. Seven replies cited a total of 67 references: 31 contained relevant original data and only 13 were controlled trials, all of which had serious methodological flaws. There were four reports of changes in advertising claims and one company ceased marketing nikethamide in the third world. Standards of evidence used to justify advertising claims are inadequate.|
|Keywords:||Product Surveillance, Postmarketing; Fraud; Developing Countries; Drug Industry; Health Promotion; Advertising as Topic; Evaluation Studies as Topic|
|Description:||Originally published as Volume 2, Issue 8674|
|Rights:||© 1989 Published by Elsevier Ltd.|
|Appears in Collections:||Public Health publications|
Files in This Item:
There are no files associated with this item.
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.